Catalog No.
RHB33408
Species reactivity
Human, Mouse, Monkey
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400, WB: 1:500-1:2000
Target
IDH1, IDH, NADP(+)-specific ICDH, Isocitrate dehydrogenase [NADP] cytoplasmic, PICD, IDP, Cytosolic NADP-isocitrate dehydrogenase, Oxalosuccinate decarboxylase
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O75874
Applications
ELISA, FCM, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R2V90
Comparative evaluation of a novel adhesive- Histoweld™ for immunohistochemistry: A non-inferiority study., PMID:40485404
F3 Expression Drives Sensitivity to the Antibody-Drug Conjugate Tisotumab Vedotin in Glioblastoma., PMID:40075681
Treatment of Relapsed/Refractory AML-Novel Treatment Options Including Immunotherapy., PMID:39960017
Unlocking the Glioblastoma Enigma: Exploring PD-L1 (Programmed Death-Ligand 1) and IDH1 (Isocitrate Dehydrogenase-1) Expression and Their Immunotherapeutic Implications., PMID:39906459
Congress of Neurological Surgeons systematic review and evidence based guideline on neuropathology for WHO grade II diffuse glioma: update., PMID:39747718
Exploring the Regulatory Mechanism of CXCL16 Molecule-Related Antigen Presentation Using lncRNA-mRNA Co-Expression Network Analysis., PMID:39735899
VGLL fusions define a new class of intraparenchymal central nervous system schwannoma., PMID:39713960
MYB::QKI fusion-positive diffuse glioma of the cerebellum: A case report., PMID:39569742
NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes., PMID:39472976
Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study., PMID:39358645
Current status and research directions in acute myeloid leukemia., PMID:39300079
cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas., PMID:39212325
Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma., PMID:39085480
Evaluation of Microvascular Density in Glioblastomas in Relation to p53 and Ki67 Immunoexpression., PMID:38928515
Prognostic Value of ATRX and p53 Status in High-Grade Glioma Patients in Morocco., PMID:38633919
Low-Grade Glioma within Mature Cystic Teratoma in a Patient with Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Case Report., PMID:38449876
Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response., PMID:38372901
Task design for crowdsourced glioma cell annotation in microscopy images., PMID:38263411
Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review., PMID:38203714
How I treat refractory and relapsed acute myeloid leukemia., PMID:37944143
Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers., PMID:37909039
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity., PMID:37793852
Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia., PMID:37509251
The Contribution of Multiplexing Single Cell RNA Sequencing in Acute Myeloid Leukemia., PMID:37489448
How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?, PMID:37457126
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma., PMID:37265425
Role of cyclin D1 in glial tumors-A retrospective and observational study., PMID:37077066
[Novel Strategies to Treat Acute Myeloid Leukemia]., PMID:36990117
TERT Immunohistochemistry as a Surrogate Marker for TERT Promoter Mutations in Infiltrating Gliomas., PMID:36952585
The Immuno-Oncology and Genomic Aspects of DNA-Hypomethylating Therapeutics in Acute Myeloid Leukemia., PMID:36835136
Characterization of an IDH1 R132H Rabbit Monoclonal Antibody, MRQ-67, and Its Applications in the Identification of Diffuse Gliomas., PMID:36810519
Metabolomics of small extracellular vesicles derived from isocitrate dehydrogenase 1-mutant HCT116 cells collected by semi-automated size exclusion chromatography., PMID:36710884
Utility of arterial spin labeling for objective assessment of intratumoral microvessels in diffuse hemispheric glioma, H3 G34R-mutant: A case report and literature review., PMID:36589502
Clinical Benefit of Bevacizumab and Irinotecan (BEV+IRI) in Patients With Relapsed/Refractory Glioblastoma (r/rGBM) and its Potential Predictors., PMID:36456153
Clinical, Therapeutic, and Prognostic Experience in Patients With Glioblastoma., PMID:36381939
Resistance to targeted therapies in acute myeloid leukemia., PMID:36318439
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL., PMID:36287248
Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma., PMID:36172668
Prospects for the use of blood elemental status to assess the molecular genetic profile of gliomas., PMID:36099457
Immunohistochemical Detection and Prognostic Significance of p53, Epidermal Growth Factor Receptor, Murine Double Minute 2, and Isocitrate Dehydrogenase 1 in Glioblastoma Multiforme Patients of Pakistan., PMID:36035640
5-Aminolevulinic Acid (5-ALA)-Induced Protoporphyrin IX Fluorescence by Glioma Cells-A Fluorescence Microscopy Clinical Study., PMID:35740509
Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma., PMID:35606087
IDH1/2 Mutations in Sinonasal Undifferentiated Carcinomas : Previously Undescribed IDH2 R172K and R140x Variants., PMID:35486703
[The phenomenon of pseudotumorous cross immunohistochemical reactivity of glia in progressive multifocal leukoencephalopathy]., PMID:35417947
New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy., PMID:35409248
Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents., PMID:35406464
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic., PMID:35318270
Multi-tracer and multiparametric PET imaging to detect the IDH mutation in glioma: a preclinical translational in vitro, in vivo, and ex vivo study., PMID:35303961
PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications., PMID:35287169
IDH1/2 Mutations in Patients With Diffuse Gliomas: A Single Centre Retrospective Massively Parallel Sequencing Analysis., PMID:35262523
For research use only. Not for human or drug use.
